{
    "clinical_study": {
        "@rank": "107409", 
        "arm_group": {
            "arm_group_label": "Pentostatin/Cyclophosphamide/Ofatumumab", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days)."
        }, 
        "brief_summary": {
            "textblock": "This is a phase II multicenter, non-comparative, open label study in older previously\n      untreated Chronic Lymphocytic Leukaemia patients, requiring therapy, aimed at defining the\n      efficacy profile (ORR, CRR and TTP) of pentostatin and cyclophosphamide given in combination\n      with Ofatumumab (PCO)."
        }, 
        "brief_title": "Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Chronic lymphocytic leukemia (CLL) is the most common of the chronic lymphoid leukemias,\n      comprising 30% of all adult leukemias. The majority of CLL patients are of advanced age.\n      Currently, immunochemotherapy with Rituximab, Fludarabine and Cyclophosphamide (RFC) is the\n      standard of care in previously untreated patients with CLL requiring treatment. The\n      combination of Pentostatin and Cyclophosphamide has generated excellent clinical response\n      rates in pretreated B-CLL patients. Early data on the use of Ofatumumab as a single agent in\n      Fludarabine-refractory CLL patients have been reported. Given the reported efficacy of\n      chemo-immunotherapy combinations in CLL and the promising activity and toxicity profile of\n      Pentostatin combinations, we designed a trial of Pentostatin, Cyclophosphamide, and\n      Ofatumumab for previously untreated older patients with CLL. The aim is improving efficacy,\n      in Rituximab resistant CLL, and toxicity considering the good profile of tolerability showed\n      using Ofatumumab as single agent."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of B-CLL defined by:\n\n               1. Circulating lymphocytes of more than or equal to 5 x109/L B lymphocytes\n                  (5000/mL) in the peripheral blood for the duration of at least 3 months. AND\n\n               2. Flow cytometry confirmation of immunophenotype: CD5, CD19, CD20, CD23, CD79b,\n                  and surface Ig\n\n          -  Age \u2265 65 years\n\n          -  Active disease and indication for treatment based on modified NCI-WG guidelines\n             defined by presenting at least any one of the following conditions:\n\n          -  Evidence of progressive marrow failure as manifested by development of, or worsening\n             of anemia and/or thrombocytopenia\n\n          -  Massive (i.e. > 6 cm below the left costal margin) or progressive or symptomatic\n             splenomegaly\n\n          -  Massive nodes (i.e. > 10 cm in longest diameter) or progressive or symptomatic\n             lymphadenopathy\n\n          -  Progressive lymphocytosis with an increase of > 50% over a two month period or an\n             lymphocyte doubling time < 6 months\n\n          -  A minimum of any one of the following disease-related symptoms must be present:\n\n               1. Unintentional Weight loss \u00b3 10% within the previous six months\n\n               2. Fevers > 38.0 \u00b0C for \u2265 2 weeks without evidence of infection\n\n               3. Night sweats for more than 1 month without evidence of infection\n\n          -  Not been previously treated for B-CLL (prior autoimmune hemolytic anemia treatment\n             permitted)\n\n          -  ECOG Performance Status of 0-2\n\n          -  Signed written informed consent prior to performing any study-specific procedures\n\n        Exclusion Criteria:\n\n          -  Prior therapy for B-CLL with any agent except corticosteroids used to treat\n             autoimmune hemolytic anemia\n\n          -  Active autoimmune hemolytic anemia (AIHA) requiring corticosteroid therapy > 100 mg\n             equivalent to hydrocortisone, or chemotherapy\n\n          -  Known Richter transformation\n\n          -  Known CNS involvement of B-CLL\n\n          -  Any radiation therapy \u2264 4 weeks prior to registration;\n\n          -  Any major surgery \u2264 4 weeks prior to registration;\n\n          -  Chronic or current infectious disease requiring systemic antibiotics, antifungal, or\n             antiviral treatment such as, but not limited to, chronic renal infection, chronic\n             chest infection with bronchiectasis, tuberculosis and active Hepatitis C\n\n          -  Past or current malignancy with the exception of basal cell carcinoma of the skin or\n             in situ carcinoma of the cervix or the breast unless the tumor was successfully\n             treated with curative intend at least 2 years prior to trial entry.\n\n          -  Clinically significant cardiac disease including unstable angina, acute myocardial\n             infarction within 6 months prior to Visit 1, congestive heart failure, and arrhythmia\n             requiring therapy, with the exception of extra systoles or minor conduction\n             abnormalities\n\n          -  History of significant cerebrovascular disease\n\n          -  Glucocorticoid unless given in doses \u2264 100 mg/day hydrocortisone (or equivalent dose\n             of other glucocorticoid) if for exacerbations other than B-CLL (e.g. asthma)\n\n          -  Known HIV positive\n\n          -  Positive serology for Hepatitis B (HB), defined as a positive test for HBsAg. In\n             addition if negative for HBsAg but HBcAb positive and HBsAb negative a HB DNA test\n             will be performed and if positive the subject will be excluded. Note: if HBcAb\n             positive and HBsAb positive, which is indicative of a past infection, the subject can\n             be included.\n\n          -  Screening laboratory values:\n\n               1. Creatinine Clearance < 60 mL/min\n\n               2. Total bilirubin > 2.0 times upper normal limit (unless due to liver involvement\n                  of BCLL)\n\n               3. ALT > 3.0 times upper normal limit (unless due to liver involvement of B-CLL)\n\n          -  Treatment with any non-marketed drug substance or experimental therapy within 4 weeks\n             prior to Visit 1 or currently participating in any other interventional clinical\n             study\n\n          -  Known or suspected inability to comply with the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681563", 
            "org_study_id": "PCO", 
            "secondary_id": "2010-022332-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pentostatin/Cyclophosphamide/Ofatumumab", 
                "description": "Lyophilized powder for intravenous administration.", 
                "intervention_name": "Pentostatin", 
                "intervention_type": "Drug", 
                "other_name": "Nipent 10 mg"
            }, 
            {
                "arm_group_label": "Pentostatin/Cyclophosphamide/Ofatumumab", 
                "description": "IV", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pentostatin/Cyclophosphamide/Ofatumumab", 
                "description": "Liquid concentrate for solution for infusion.", 
                "intervention_name": "Ofatumumab", 
                "intervention_type": "Drug", 
                "other_name": "Arzerra 100 mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Pentostatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MB", 
                        "zip": "20052"
                    }, 
                    "name": "Azienda Ospedaliera San Gerardo di Monza U.O. Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy", 
                        "state": "Milano", 
                        "zip": "20089"
                    }, 
                    "name": "IRCCS Istituto clinico Humanitas di Rozzano Dipartimento di Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Legnano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20025"
                    }, 
                    "name": "Azienda Ospedaliera Ospedale Civile di Legnano U.O. Medicina Interna"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Venezia Mestre", 
                        "country": "Italy", 
                        "state": "VE", 
                        "zip": "30174"
                    }, 
                    "name": "Ospedale dell' Angelo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "zip": "24128"
                    }, 
                    "name": "A.O. Papa Giovanni XXIII U.S.C. Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "zip": "25125"
                    }, 
                    "name": "Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Como", 
                        "country": "Italy", 
                        "zip": "22100"
                    }, 
                    "name": "Ospedale Valduce S.C. Medicina Interna Sez. Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cremona", 
                        "country": "Italy", 
                        "zip": "26100"
                    }, 
                    "name": "Istituti Ospitalieri di Cremona U.O.C. Ematologia e Centro Trapianti Midollo Osseo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodi", 
                        "country": "Italy", 
                        "zip": "26900"
                    }, 
                    "name": "ASL della Provincia di Lodi Presidio Ospedaliero di Lodi Dipartimento di Medicina Interna"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20132"
                    }, 
                    "name": "IRCCS Fondazione Centro S. Raffaele del Monte Tabor Universit\u00e0 Vita-Salute Dipartimento di Medicina Interna"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20162"
                    }, 
                    "name": "Ospedale C\u00e0 Granda - Niguarda S.C: Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20122"
                    }, 
                    "name": "Ospedale Maggiore Policlinico Universit\u00e0 di Milano Istituto di Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novara", 
                        "country": "Italy", 
                        "zip": "28100"
                    }, 
                    "name": "Azienda ospedaliera-universitaria Maggiore della Carit\u00e0 SCDU Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "zip": "27100"
                    }, 
                    "name": "IRCCS Policlinico San Matteo Pavia Istituto di Ematologia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "A.O.U. Le Molinette San Giovanni Battista Divisione di Ematologia"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm Multi-center Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia", 
        "overall_official": [
            {
                "affiliation": "Ospedale C\u00e0 Granda - Niguarda S.C: Ematologia", 
                "last_name": "Marco Montillo, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Ospedale Maggiore Policlinico Universit\u00e0 di Milano Istituto di Ematologia", 
                "last_name": "Agostino Cortelezzi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ASL della provincia di Lodi Presidio Ospedaliero di Lodi Dipartimento di Medicina Interna", 
                "last_name": "Giovanni Ucci, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "IRCCS Policlinico San Matteo Pavia Istituto di Ematologia", 
                "last_name": "Ester Orlandi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Azienda Ospedaliera San Gerardo di Monza U.O. Ematologia", 
                "last_name": "Fausto Rossini, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "IRCCS Istituto Clinico Humanitas di Rozzano Dipartimento di Ematologia", 
                "last_name": "Armando Santoro, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "IRCCS Ospedale S. Raffaele Universit\u00e0 Vita-Salute Dipartimento di Medicina Interna", 
                "last_name": "Paolo Ghia, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia", 
                "last_name": "Marina Motta, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0 - Struttura Complessa a Direzione Universitaria (SCDU Ematologia)", 
                "last_name": "Gianluca Gaidano, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ospedale Valduce S.C. Medicina Interna Sezione di Ematologia", 
                "last_name": "Roberto Cairoli, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Istituti Ospitalieri di Cremona U.O.Complessa di Ematologia e CTMO", 
                "last_name": "Pierangelo Spedini, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AOU Le Molinette San Giovanni Battista Divisione di Ematologia", 
                "last_name": "Massimo Massaia, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Azienda Ospedaliera Ospedale Civile di Legnano U.O. Medicina Interna", 
                "last_name": "Antonino Mazzone, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "A.O. Papa Giovanni XXIII di Bergamo USC Ematologia", 
                "last_name": "Alessandro Rambaldi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ospedale dell' Angelo Venezia Mestre", 
                "last_name": "Renato Bassan, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: The Italian Medicines Agency", 
                "Italy: Coordinating center administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the overall response rate (ORR) using pentostatin, cyclophosphamide, and ofatumumab in patients with previously untreated CLL requiring therapy.", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "2 months after the last dose received (End of treatment period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To monitor and assess toxicity of pentostatin, cyclophosphamide, and ofatumumab in patients with previously untreated CLL.", 
                "measure": "Adverse Events according to CTCAE, Version 3.0 NCI CTCAE", 
                "safety_issue": "No", 
                "time_frame": "From informed consent signed through to 28 days after the last study drug administration"
            }, 
            {
                "description": "To assess the complete response of CLL patients treated with pentostatin, cyclophosphamide, and ofatumumab", 
                "measure": "Complete Response Rate (CRR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at cycle 3 and 2 months after the last dose received"
            }, 
            {
                "description": "To determine the proportion of patients who achieve a minimal residual disease (MRD) negative state as assessed by flow cytometry.It will be assessed only in patients responding to PCO treatment.", 
                "measure": "Minimal Residual Disease (MRD)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months from the last dose of treatment up to 2 years follow up."
            }, 
            {
                "description": "To determine the progression-free survival in CLL patients treated with pentostatin,cyclophosphamide, and ofatumumab.", 
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Measured as the time from inclusion in the trial to disease progression or death, assessed up to  2 years"
            }, 
            {
                "description": "To assess overall survival (OS) of CLL patients treated with pentostatin, cyclophosphamide, and ofatumumab", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Measured as the time from inclusion in the trial until death from any cause, assessed up to 2 years of follow up"
            }, 
            {
                "description": "To assess the time-to-progression (TTP) of CLL patients treated with pentostatin, cyclophosphamide, and ofatumumab", 
                "measure": "Time To Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "Measured as the time from inclusion in the trial until disease progression or death, assessed up to 2 years"
            }, 
            {
                "description": "To determine if cytogenetic abnormalities identified by FISH, relate to response to PCO therapy.", 
                "measure": "Genetic analysis by Fish", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 months after the last dose received  and at month 12 and 24 during follow up"
            }, 
            {
                "description": "To assess ofatumumab pharmacokinetic parameters", 
                "measure": "Ofatumumab pharmacokinetics parameter", 
                "safety_issue": "No", 
                "time_frame": "Cycle1: Day 1, 2, 3, 8, 9, 15. Cycles 2-5: Day 1, 2, 3, 8,15. Cycle 6: Day 1, 2, 3, 8, 15, 21"
            }, 
            {
                "description": "To determine if IgVH mutation status relate to response to PCO therapy", 
                "measure": "IgVH mutation status", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 months after the last dose received and at month 12 and 24 during follow up"
            }
        ], 
        "source": "Niguarda Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Regione Lombardia", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Hospira, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Niguarda Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}